London-based IMU Biosciences has closed an oversubscribed extension to its Series A financing round, bringing the total raise to over USD 53 million (GBP 40 million) as the company advances its immune profiling platform and expands its clinical programs.
The IMU Biosciences Series A financing was co-led by IQ Capital and Molten Ventures, with participation from the British Business Bank, Meltwind, and existing investors. The round brings total capital raised by the company to USD 60 million. Proceeds will be directed toward operational expansion, clinical platform infrastructure, and the advancement of active programs in stem cell transplantation, solid organ transplantation, and immuno-oncology, including a UK research consortium called MANIFEST, which is investigating patient response to cancer immunotherapies.
IMU was founded by experimental immunologists and computational biologists with backgrounds at the Francis Crick Institute and King's College London. The company's core technology combines high-fidelity multi-omic analysis with proprietary machine learning analytics, enabling the measurement of over 100 million immune data points from a single blood sample.
The company said it has assembled what it describes as the world's largest immune dataset, now scaling to more than 25,000 individuals in 2026, built through access to patient samples and population-wide clinical data. IMU is positioning this dataset as the basis for a universal standard in immune profiling — one designed to support disease mechanism discovery, treatment monitoring, and patient-level prediction of therapeutic response.
Active clinical programs span stem cell and bone marrow transplantation, solid organ transplantation, and the MANIFEST immuno-oncology consortium. The company said it is advancing its platform across immune-mediated diseases more broadly, though specific drug candidates or regulatory milestones were not disclosed in the announcement.